Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
What is PT-141?
PT-141, known by its drug name bremelanotide, is a synthetic analog of the neuropeptide alpha-melanocyte-stimulating hormone (α-MSH). It binds with high affinity to the melanocortin type-4 receptor (MC4R), which is thought to be involved in central nervous-system pathways relevant to sexual response (Dhillon & Keam, 2019).
Regulatory and research context
Bremelanotide (Vyleesi) received its first regulatory approval from the U.S. FDA in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) — administered as an on-demand subcutaneous injection. It progressed through Phase 3 clinical trials before approval (Dhillon & Keam, 2019).
How it is thought to work
Unlike vascular-acting agents, PT-141 acts centrally through MC4R to modulate brain pathways involved in sexual desire — a distinct mechanism that made it of scientific interest.
The limits and important context
- Its approval is narrow and specific (premenopausal HSDD) and use is under medical supervision — this does not extend to other populations or uses.
- The material referenced here is supplied for laboratory research use only and is not for human use.
References
According to PubMed:
- Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019. doi:10.1007/s40265-019-01187-w
